Physician
Mark a Perez, M.D., LLC
Mark a Perez, M.D., LLC was paid $542K by Medicaid between Jan 2018 and Dec 2024, across 52 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 46% of everything it billed.
33Billing provider infoMARK A PEREZ, M.D., LLC
LAS VEGAS, NV 89119
LAS VEGAS, NV 89119
33aNPI1083962856assigned 08/27/2012
33bProvider typeFamily Medicine Physician
28Total paid$542K
24GClaims29,824
24DCodes billed52
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Nevada
Rank by total paid#46 of 388
Median peer was paid$27K
This provider vs. median20×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,386 | $62K | |
| 2019 | 4,789 | $92K | |
| 2020 | 4,002 | $89K | |
| 2021 | 5,401 | $98K | |
| 2022 | 4,763 | $85K | |
| 2023 | 5,297 | $81K | |
| 2024incomplete | 2,186 | $35K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 46% | 5,317 | 4,663 | $249K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 44% | 7,439 | 5,972 | $241K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 5.6% | 3,571 | 2,592 | $31K |
| 93000 | 1.2% | 908 | 745 | $6K | |
| 82962 | <1% | 3,745 | 2,957 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,956 | 1,529 | $2K |
| 36416 | <1% | 1,536 | 1,301 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 240 | 158 | $1K |
| 81002 | <1% | 1,204 | 994 | $925.44 | |
| 20610 | <1% | 61 | 39 | $890.38 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 47 | 39 | $867.78 |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 70 | 70 | $830.86 |
40 more codes
| A4556 | Electrodes, (e.g., apnea monitor), per pair | <1% | 73 | $816.09 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 102 | $810.92 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 16 | $791.28 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 30 | $713.30 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 115 | $514.10 |
| 90688 | <1% | 90 | $264.78 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 20 | $238.73 |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 34 | $202.38 |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 33 | $168.08 |
| 90686 | <1% | 20 | $159.75 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 62 | $154.57 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 57 | $137.39 |
| 90674 | <1% | 35 | $120.72 | |
| 97010 | <1% | 60 | $113.28 | |
| 99442 | <1% | 13 | $99.68 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 12 | $98.40 |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | <1% | 71 | $65.54 |
| 83014 | <1% | 30 | $59.98 | |
| 0013A | <1% | 14 | $37.82 | |
| 94760 | <1% | 55 | $37.32 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 81 | $27.82 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 129 | $6.62 |
| G0008 | Administration of influenza virus vaccine | 0% | 98 | $0.00 |
| H0033 | Oral medication administration, direct observation | 0% | 122 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 70 | $0.00 |
| 2000F | 0% | 372 | $0.00 | |
| 2010F | 0% | 426 | $0.00 | |
| 99000 | 0% | 223 | $0.00 | |
| 3008F | 0% | 508 | $0.00 | |
| 3074F | 0% | 195 | $0.00 | |
| 3079F | 0% | 169 | $0.00 | |
| 3075F | 0% | 51 | $0.00 | |
| 3044F | 0% | 45 | $0.00 | |
| 1125F | 0% | 53 | $0.00 | |
| 3080F | 0% | 14 | $0.00 | |
| 3011F | 0% | 14 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 33 | $0.00 |
| 91306 | 0% | 14 | $0.00 | |
| 3077F | 0% | 48 | $0.00 | |
| 3078F | 0% | 123 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPEREZ, MARK (MEDICAL DIRECTOR)